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interaction of isoflavones and 
endophyte-infected tall fescue seed 
extract on vasoactivity of bovine 
mesenteric vasculature
Yang Jia1 , David L. Harmon1 , Michael D. Flythe2 and James L. Klotz2*
1 Department of Animal and Food Sciences, University of Kentucky, Lexington, KY, USA, 2 Forage-Animal Production 
Research Unit, Agricultural Research Service, United States Department of Agriculture, Lexington, KY, USA
It was hypothesized that isoflavones may attenuate ergot alkaloid-induced vasoconstric-
tion and possibly alleviate diminished contractility of vasculature after exposure to ergot 
alkaloids. The objective of this study was to determine if prior incubation of bovine mes-
enteric vasculature with the isoflavones formononetin (F), biochanin A (B), or an ergov-
aline-containing tall fescue seed extract (EXT) and their combinations affect ergotamine 
(ERT)-induced contractility. Multiple segments of mesenteric artery and vein supporting 
the ileal flange of the small intestine were collected from Angus heifers at slaughter (n = 5, 
bodyweight = 639 ± 39 kg). Duplicates of each vessel type were incubated in tissue cul-
ture flasks at 37°C with a 50-mL volume of Krebs–Henseleit buffer containing: only buffer 
(control); or 1 × 10−6 M EXT; F; or B; and combinations of 1 × 10−6 M EXT + F; 1 × 10−6 M 
EXT + B; 1 × 10−6 M F + B; or 1 × 10−6 M EXT + F + B. After incubation for 2 h, sections 
were mounted in a multimyograph chamber. The ERT dose responses were normalized 
to 0.12 M KCl. Pretreatment with F, B, and F + B without EXT resulted in similar contrac-
tile responses to ERT in mesenteric artery and all incubations containing EXT resulted in a 
complete loss of vasoactivity to ERT. In mesenteric artery pretreated with EXT, treatments 
that contained B had higher contractile responses (P < 0.05) at ERT concentrations of 
1 × 10−7 and 5 × 10−7 M. Also, treatments containing B tended (P < 0.1) to have greater 
responses than treatments without B at ERT concentrations of 1 × 10−6, 5 × 10−6, and 
5 × 10−5 M. In mesenteric vein pretreated with EXT, treatments containing F had greater 
contractile responses to ERT at 1 × 10−5, 5 × 10−5, and 1 × 10−4 M (P < 0.05). These 
data indicated that F and B at 1 × 10−6 M and their combination did not impact the overall 
contractile response to ERT in mesenteric vasculature. However, F and B may offset 
some of the vasoconstriction caused by prior exposure to ergot alkaloids.
Keywords: ergot alkaloids, isoflavones, mesenteric vasculature, vasoconstriction
inTrODUcTiOn
As a symbiotic endophyte of tall fescue (Lolium arundinaceum) (1–4), Epichloë coenophiala 
produces a variety of ergot alkaloids (5, 6), which have been identified as causative agents of 
vasoconstriction and symptoms of fescue toxicosis in grazing animals (7, 8). Ergovaline and 
ergotamine commonly draw more attention of researchers. Lyons et al. (5) reported that ergovaline 
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was the predominant (84–97%) alkaloid of all the five detected 
ergopeptine alkaloids from tall fescue (Lolium arundinaceum) 
pasture. Numerous studies have reported that ergot alkaloids 
(ergovaline and ergotamine) induce vasoconstriction in 
peripheral blood vessel models such as the caudal artery (9, 
10), dorsal pedal vein (11), and lateral saphenous vein (12), 
and also core blood vessel models like the right ruminal artery 
and vein (13), bovine uterine and umbilical arteries (14), and 
mesenteric artery and vein (15). Consistent with findings in 
the bovine lateral saphenous vein (16, 17), Egert et  al. (15) 
demonstrated that previous dietary exposure to ergot alkaloids 
reduced the vasoactivity in bovine mesenteric vasculature.
Isoflavones are almost exclusively found in the legume 
(Leguminosae/Fabaceae) family, such as soybean, chickpeas, and 
red clover (18, 19). A variety of isoflavones, such as genistein, 
daidzein, biochanin A (B), and formononetin (F), have been 
shown to elicit different beneficial effects on humans in many 
different ways, for example, improvements to the cardiovascular 
system, osteoporosis, anti-breast, and prostate cancer (20–23). 
Substantial evidence has been published on the vasodilative 
effects of isoflavones and their metabolites in different vessel 
types in humans (24, 25) and rats (26–29). However, based on our 
knowledge, no studies have investigated the vasodilative effects of 
isoflavones on bovine vessels.
Ergot alkaloids share some structural similarities with 
biogenic amines (i.e., dopamine, epinephrine, norepinephrine, 
serotonin) and thus can cause vasoconstriction by binding 
biogenic amine receptors (30) found throughout the body. On 
the other hand, isoflavones have estrogenic activities and could 
cause endothelium-dependent or -independent vasorelaxation. 
Although the precise mechanisms behind the vascular bioactivity 
of both ergot alkaloids and isoflavones have not been fully defined, 
current knowledge suggests that they are triggered by different 
mechanisms. Nevala et  al. (31) reported that isoflavones relax 
noradrenaline precontracted rat mesenteric arteries. Likewise, 
Egert et  al. (15) demonstrated that ergot alkaloids were vaso-
constrictive in bovine mesenteric vasculature, whereas dietary 
exposure to ergot alkaloids decreased the contractility of mesen-
teric vasculature. Thus, it was hypothesized that isoflavones may 
attenuate ergot alkaloid-induced vasoconstriction and possibly 
alleviate the diminished contractility of mesenteric vasculature 
after preliminary exposure to ergot alkaloids. The objective of 
this study was to determine if an incubation of bovine mesenteric 
vasculature with F, B, or ergovaline-containing tall fescue seed 
extract (EXT) and their combinations affect ergotamine (ERT)-
induced contractility.
MaTerials anD MeThODs
No live animals were involved this study, so approval from the 
University of Kentucky Animal Care and Use Committee was not 
required.
animals and Tissue collection
Five Angus heifers (Bodyweight =  639 ±  39  kg) were slaugh-
tered and tissues were collected at the University of Kentucky 
abattoir. As originally described by Klotz and Barnes (32), the 
gastrointestinal tract was removed from the carcass, and the 
cecum, ileocecal fold, and the ileal flange were identified as 
landmarks. Within the mesentery supporting the ileal flange, 
multiple branches of the mesenteric artery and vein bundles 
were dissected and submerged in oxygenated Krebs–Henseleit 
buffer (95% O2/5% CO2; pH = 7.4; 11.1 mM d-glucose; 1.2 mM 
MgSO4; 1.2 mM KH2PO4; 4.7 mM KCl; 118.1 mM NaCl; 3.4 mM 
CaCl2; 24.9 mM NaHCO3; Sigma Chemical Co., St. Louis, MO, 
USA) for transport to the laboratory. Samples were stored on 
ice until cleaned. At the time of cleaning, surrounding fat and 
connective tissues were carefully removed, and mesentery artery 
and vein were separated under a magnifying lamp (2.5 to 5.0× 
magnification). Cleaned vessels were sliced into 2-mm segments 
and examined under a dissecting scope (Semi 2000-C, Carl Zeiss 
Inc., Oberkochen, Germany) at 12.5× magnification to ensure 
the usability of the vessels. Cross-sections with abnormalities 
(branches, valves, or structural damage) were replaced with 
structurally integral ones.
Pre-Myograph incubations
A tall fescue seed extract was prepared as described by Foote et al. 
(33) to contain a 1 × 10−6 M working concentration of ergovaline. 
Duplicates of each vessel type (from each animal) were incubated 
in tissue culture flasks with a 50-mL volume of Krebs–Henseleit 
buffer containing: only buffer (control); 1  ×  10−6  M EXT; 
1 × 10−6 M F (≥99.0%; 47752-5MG-F; Sigma Chemical Co., St. 
Louis, MO, USA); or 1 × 10−6 M B (D2016; Sigma Chemical Co., 
St. Louis, MO, USA); and combinations of 1 × 10−6 M EXT + F; 
1 × 10−6 M EXT + B; 1 × 10−6 M F + B; or 1 × 10−6 M EXT + F + B. 
All buffer solutions were prewarmed for 30 min in a CO2 incuba-
tor (95% O2/5% CO2; 37°C; Nu-8500, NUAIRE, Inc., Plymouth, 
MN, USA) prior to blood vessel addition. Duplicate blood vessel 
segments were randomly placed into each treatment flask and 
incubated in the same conditions for 2 h. Immediately after the 
2-h incubation, dimensional measurements of cross-sections 
were recorded only for mesentery artery using Axiovision (ver-
sion 20, Carl Zeiss, Inc.).
experimental Myograph Protocol
Following the 2-h incubations, an ERT concentration response 
experiment was conducted using the procedures described by 
Klotz and Barnes (32). ERT (ergotamine d-tartrate; 97%; 45510; 
Aldrich, Milwaukee, WI, USA) standards were prepared by 
diluting a stock solution (0.0201 M) with dimethyl sulfoxide to 
working concentrations that resulted in a concentration range of 
5 × 10−9 to 1 × 10−4 M in the myograph chamber (contained 5 mL 
of Krebs–Henseleit buffer).
Artery and vein cross-sections were mounted on the myo-
graph (Multichamber myograph; DMT 610M, Danish Myo 
Technology, Atlanta, GA, USA) by inserting the supports through 
the lumen in individual myograph chambers containing 5  mL 
modified Krebs–Henseleit buffer and continuously gassed (95% 
O2/5% CO2; pH = 7.4; 37°C). The incubation buffer was modified 
from transport Krebs–Henseleit buffer by adding desipramine 
(3 × 10−5 M; D3900; Sigma Chemical Co.) to inhibit the reuptake 
mechanisms of biogenic amines and propranolol (1 ×  10−6  M; 
P0844; Sigma Chemical Co.) to block the non-specific binding 
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of ERT to β-adrenergic receptors. A 90-min equilibration period 
with buffer replacement occurring every 15 min was completed 
based on the conditions above to achieve a stable resting tension 
of approximately 1  g. Following the equilibration period, the 
blood vessels were exposed to 120 mM KCl for 15 min to evaluate 
tissue viability and to normalize treatment data. Following the 
KCl addition, the incubation buffer was replaced every 15 min 
until vessel tension returned to the 1 g baseline. Once the vessel 
returned to baseline, addition of ERT standards was initiated in 
order to increase the concentration. ERT additions were added 
in 15-min intervals consisting of a 9-min-incubation period, two 
2.5-min buffer washes, and a third, final buffer replacement that 
was followed by 1-min recovery before the next ERT addition. 
This 15 min cycle was repeated for the rest of the nine remaining 
ERT additions. Following the 1-min recovery after the final ERT 
addition, vessels were again exposed to 120 mM KCl to confirm 
the vessel viability at the end of the experiment.
Data collection
The isometric contractions of the different preincubated mes-
enteric vessels to KCl and ERT additions were digitized and 
recorded as grams of tension using a PowerLab/8sp and Chart 
software (version 7.3, ADInstruments, Colorado Springs, Co.). 
Baseline tension was measured immediately before the addition 
of 120 mM KCl. For all contractile response data, the maximum 
observed tension (in grams) in the 9 min-incubation period was 
recorded as the contractile response. Contractile response data 
were corrected for baseline tension and normalized as a percent-
age of the reference compound KCl induced maximum contractile 
response. The differences of tissue response due to the variations 
of vessel size and across individual animal were minimized by 
this data normalization. The contractile response to ERT was 
determined and presented as percentage means ± SEM. A meas-
urement of potency or the half-maximal effective concentration 
(EC50) was calculated using GraphPad Prism (version 5; GraphPad 
Software Inc., La Jolla, CA, USA) using a non-linear regression 
with fixed slope. The sigmoidal concentration response curves of 
pretreated mesentery artery and vein to ERT was plotted by using 
a three-parameter equation:
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where y represents contractile response, and x denotes the agonist 
concentration, top and bottom are the plateaus of contractile 
response as percentage of 120 mM KCl maximum response. The 
EC50 is the molar concentration of ERT inducing 50% of the KCl 
maximum response.
statistics
All data were analyzed using the MIXED model of SAS (SAS 9.4, 
SAS Inst. Inc., Cary, NC, USA). Contractile response data of mes-
entery artery and vein were analyzed separately as two datasets for 
treatments with and without EXT. Data for contractile response 
(within each ERT concentration), KCl maximal response, inside 
and outside diameters for mesenteric artery (these data could not 
be obtained for mesenteric vein samples due to the pliable nature 
of this vessel) were analyzed as a completely randomized design 
with a factorial treatment arrangement. The fixed effects included 
the effects of F, B, and the interaction of F × B in the presence or 
absence of EXT. Due to the shape of the response curve, EC50 data 
were analyzed only in treatments without EXT from mesentery 
artery using a completely randomized design with treatment as 
fixed variable. For all data, pair-wise comparisons of least square 
means (±SEM) were only performed if the probability of a greater 
F-statistic from the analysis of variance was significant for the 
tested effect and interaction. Mean separation was performed 
with the LSD feature of SAS. Differences are denoted as significant 
at P < 0.05, unless specifically reported otherwise.
resUlTs
The F and B incubation pretreatment did not impact (P > 0.05) 
the maximum contractile response of mesenteric artery or 
mesenteric vein to 120 mM KCl either without EXT (Table 1) 
or with EXT (Table  2). The pretreatments with EXT did not 
compromise the vessel viability, which was indicated by the end-
ing response to KCl for either the artery or vein (Figure 1). In 
mesenteric artery, the inside and outside diameters after the 2 h 
incubation were not affected (P > 0.05) by F or B in both treat-
ment groups with (Table 2) or without EXT (Table 1). However, 
there was a tendency (P = 0.07) for F treated vessels to have a 
larger inside diameter for those pretreated with EXT (Table 2), 
and a smaller outside diameter (P = 0.09) for those not pretreated 
with EXT (Table 1). Interestingly, mesenteric artery pretreated 
with B tended (P = 0.06) to have a smaller inside diameter when 
incubated with EXT (Table 2).
In the mesenteric artery, ERT induced similar contractile 
responses in all treatments (Figure  2) with −logEC50 values 
(5.99 ± 0.14, 5.80 ± 0.14, 5.88 ± 0.14, 5.74 ± 0.14 M, respec-
tively) that did not differ with each other (P =  0.63). Within 
each ERT concentration, tendencies for F ×  B interactions in 
mesenteric artery were observed at ERT 5 ×  10−9, 1 ×  10−8, 
5 × 10−8 M (P = 0.09, P = 0.07, P = 0.08, respectively; Table 3) for 
treatments without EXT. Contractile responses of F + B treated 
mesentery artery were greater than B at ERT concentrations 
1 × 10−8 and 5 × 10−8 M (P < 0.05). In mesenteric vein, ERT-
induced contractile responses reached the maximum response 
at 1 × 10−6 M for Control, B, F, F + B treatments (Figure 3), and 
then relaxed to negative response values with increases in ERT 
concentration.
For the blood vessels incubated with EXT, the contractile 
responses decreased as the concentration of ERT increased in 
both mesenteric artery (Figure 4) and mesenteric vein (Figure 5). 
In mesenteric artery, a main effect of B was observed at ERT con-
centrations of 1 × 10−7 and 5 × 10−7 M (Table 4), with treatments 
that contained B having higher contractile responses (P < 0.05). 
Also, treatments containing B tended (P < 0.1) to have greater 
responses than treatments without B at ERT concentrations of 
1 × 10−6, 5 × 10−6, and 5 × 10−5 M (Table 4).
In the mesenteric vein, the contractile response of all treat-
ments with EXT to ERT decreased and remained below zero 
from the second ERT addition (1 × 10−8 M) to the last addition at 
TaBle 2 | inside diameter, outside diameter, and seM of mesenteric artery, and the mean Kcl maximum response of mesenteric artery and vein 
to pretreatment with tall fescue seed extract: 1 × 10−6 M ergovaline-containing tall fescue seed extract (eXT); combinations of 1 × 10−6 M eXT and 
formononetin (F), eXT and biochanin a (B), and the combination of eXT + F + B.
item eXT eXT + F eXT + B eXT + F + B seM P-value
F B F × B
Mesenteric artery
KCl maximum response (g) 3.43 2.68 3.08 2.84 0.37 0.19 0.80 0.50
Inside diameter (mm) 0.72 0.78 0.60 0.72 0.05 0.07 0.06 0.50
Outside diameter (mm) 1.64 1.57 1.51 1.59 0.07 0.92 0.43 0.29
Mesenteric veina
KCl maximum response (g) 1.90 2.20 2.09 2.49 0.21 0.11 0.26 0.81
aDue to the elasticity of the mesenteric vein, measurements of vascular dimensions were not possible.
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TaBle 1 | inside diameter, outside diameter, and seM of mesenteric artery, and the mean Kcl maximum response of mesenteric artery and vein 
to pretreatment without tall fescue extract: only Krebs–henseleit buffer (control); 1 × 10−6 M treatments of formononetin (F), biochanin a (B), and 
combination of F and B (F + B).
item control F B F + B seM P-value
F B F × B
Mesenteric artery
KCl maximum response (g) 4.36 4.42 4.22 3.66 0.46 0.58 0.33 0.50
Inside diameter (mm) 0.81 0.79 0.86 0.77 0.06 0.38 0.77 0.61
Outside diameter (mm) 1.72 1.64 1.75 1.57 0.07 0.09 0.74 0.47
Mesenteric veina
KCl maximum response (g) 1.70 1.81 1.89 2.22 0.21 0.31 0.18 0.62
aDue to the elasticity of the mesenteric vein, measurements of vascular dimensions were not possible.
FigUre 1 | example of a typical response of mesenteric artery (a) and vein (B) cross-sections, after pretreated with 1 × 10−6 M eXT and 1 × 10−6 M F 
and 1 × 10−6 M B (eXT + F + B), to increasing concentrations of erT (5 × 10−9 to 1 × 10−4 M). The rectangles highlighted regions are the initial and end KCl 
(0.12 M) additions.
FigUre 2 | Mean contractile response, as % Kcl maximum of 
mesenteric artery to increasing concentrations of ergotamine for 
pretreatments without tall fescue seed extract: only Krebs–henseleit 
buffer (control); 1 × 10−6 M formononetin (F); or 1 × 10−6 M biochanin a 
(B); and combination of 1 × 10−6 M F and 1 × 10−6 M B (F + B). The 
regression lines were plotted for each treatment using a non-linear regression 
with fixed slope, and the sigmoidal concentration response curves were 
calculated by the following equation: y EC x= + +bottom (top-bottom)/(1 10 )(log ) ,50−  
where top and bottom are the plateaus of contractile response as percentage of 
120 mM KCl maximum response. EC50 is the molar concentration of ergotamine 
inducing 50% of the KCl maximum response.
TaBle 3 | The analysis of variance and P-values of main effect of 
formononetin (F), biochanin a (B), and the interaction of formononetin 
and biochanin a (F × B) for pretreatments without tall fescue extract: 
only Krebs–henseleit buffer; 1 × 10−6 M F, B, and combination of F and B 
on every ergotamine concentration.
ergotamine concentration (M) P-value
F B F × B
Mesenteric artery
5 × 10−9 0.23 0.91 0.09
1 × 10−8 0.14 0.27 0.07
5 × 10−8 0.20 0.51 0.08
1 × 10−7 0.29 0.83 0.31
5 × 10−7 0.88 0.79 0.43
1 × 10−6 0.68 0.78 0.64
5 × 10−6 0.27 0.99 0.72
1 × 10−5 0.38 0.97 0.97
5 × 10−5 0.43 0.81 0.77
1 × 10−4 0.61 0.54 0.59
Mesenteric vein
5 × 10−9 0.92 0.27 0.85
1 × 10−8 1.00 0.96 0.50
5 × 10−8 0.67 0.67 0.28
1 × 10−7 0.80 0.64 0.41
5 × 10−7 0.99 0.43 0.74
1 × 10−6 0.93 0.30 0.70
5 × 10−6 0.78 0.43 0.70
1 × 10−5 0.50 0.80 0.62
5 × 10−5 0.29 0.93 0.61
1 × 10−4 0.23 0.86 0.89
FigUre 3 | Mean contractile response, as % Kcl maximum of 
mesenteric vein to increasing concentrations of ergotamine for 
pretreatments without tall fescue seed extract: only Krebs–
henseleit buffer (control); 1 × 10−6 M formononetin (F); or 
1 × 10−6 M biochanin a (B); and combination of 1 × 10−6 M F and 
1 × 10−6 M B (F + B). The regression lines were plotted for each 
treatment using a non-linear regression with fixed slope, and the sigmoidal 
concentration response curves were calculated by the following equation: 
y EC x=  bottom (top-bottom)/(1 10 )+ +
−(log ) ,50  where top and bottom are the 
plateaus of contractile response as percentage of 120 mM KCl maximum 
response. EC50 is the molar concentration of ergotamine inducing 50% of the 
KCl maximum response.
FigUre 4 | Mean contractile response, as % Kcl maximum of 
mesenteric artery to increasing concentrations of ergotamine for 
pretreatments with tall fescue seed extract: 1 × 10−6 M ergovaline-
containing tall fescue seed extract (eXT); combinations of 
1 × 10−6 M eXT and 1 × 10−6 M F (eXT + F); 1 × 10−6 M eXT and 
1 × 10−6 M B (eXT + B); or 1 × 10−6 M eXT and 1 × 10−6 M F and 
1 × 10−6 M B (eXT + F + B). The regression lines were plotted for each 
treatment using a non-linear regression with fixed slope, and the sigmoidal 
concentration response curves were calculated by the following equation: 
y EC x=  
−bottom (top-bottom)/(1 10 )+ + (log ) ,50  where top and bottom are the 
plateaus of contractile response as percentage of 120 mM KCl maximum 
response. EC50 is the molar concentration of ergotamine inducing 50% of 
the KCl maximum response.
October 2015 | Volume 2 | Article 325
Jia et al. Vascular interaction of ergot alkaloids and isoflavones
Frontiers in Nutrition | www.frontiersin.org
greater contractile responses to ERT at 1 × 10−5, 5 × 10−5, and 
1 × 10−4 M in mesenteric vein (main effect of F; P < 0.05; Table 4). 
Within the 5 × 10−5 M ERT concentration, the contractile response 
of EXT was the lowest (P = 0.03).
1 × 10−4 M. Tendencies for main effects of B (P = 0.06) and F × B 
interaction (P = 0.09) were observed at ERT concentrations of 
5 × 10−9 M, where EXT treatment had a lower contractile response 
than EXT + B (P < 0.05; Table 4). Treatments containing F had 
FigUre 5 | Mean contractile response, as % Kcl maximum of 
mesenteric vein to increasing concentrations of ergotamine for 
pretreatments with tall fescue seed extract: 1 × 10−6 M ergovaline-
containing tall fescue seed extract (eXT); combinations of 
1 × 10−6 M eXT and 1 × 10−6 M F (eXT + F); 1 × 10−6 M eXT and 
1 × 10−6 M B (eXT + B); or 1 × 10−6 M eXT and 1 × 10−6 M F and 
1 × 10−6 M B (eXT + F + B). The regression lines were plotted for each 
treatment using a non-linear regression with fixed slope, and the sigmoidal 
concentration response curves were calculated by the following equation: 
y EC x= + +bottom (top-bottom)/(1 10 )(log ) ,50−  where top and bottom are the 
plateaus of contractile response as percentage of 120 mM KCl maximum 
response. EC50 is the molar concentration of ergotamine inducing 50% of 
the KCl maximum response.
TaBle 4 | The analysis of variance and P-values of main effect of 
formononetin (F), biochanin a (B), and the interaction of formononetin 
and biochanin a (F × B) for pretreatments with tall fescue seed extract 
(eXT): 1 × 10−6 M (eXT); combinations of 1 × 10−6 M eXT and F, eXT and 
B, or 1 × 10−6 M eXT + B + F on every ergotamine concentration.
ergotamine concentration (M) P-value
F B F × B
Mesenteric artery
5 × 10−9 0.94 0.71 0.70
1 × 10−8 0.43 0.31 0.96
5 × 10−8 0.22 0.11 0.77
1 × 10−7 0.20 0.04 0.73
5 × 10−7 0.25 0.03 0.57
1 × 10−6 0.21 0.06 0.58
5 × 10−6 0.21 0.09 0.52
1 × 10−5 0.31 0.13 0.70
5 × 10−5 0.24 0.10 0.87
1 × 10−4 0.18 0.12 0.77
Mesenteric vein
5 × 10−9 0.75 0.07 0.10
1 × 10−8 0.91 0.77 0.41
5 × 10−8 0.45 0.98 0.50
1 × 10−7 0.18 0.85 0.32
5 × 10−7 0.15 0.48 0.19
1 × 10−6 0.19 0.58 0.32
5 × 10−6 0.16 0.44 0.27
1 × 10−5 0.03 0.30 0.12
5 × 10−5 0.02 0.17 0.08
1 × 10−4 0.01 0.24 0.14
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DiscUssiOn
This is the first study to investigate the interaction of ergot alkaloids 
and isoflavones on bovine mesenteric vasculature. Physiological 
effects of isoflavones and their metabolites on vasculature have 
been extensively studied on different vessel types in humans (24, 
25) and rat models (26–29). The concentrations of isoflavones 
(1 × 10−6 M formononetin and biochanin A) used in the current 
experiment were based on a study that reported dose-dependent 
formononetin- and biochanin A-induced relaxations of rat-
isolated thoracic aorta precontracted with phenylephrine (29). 
At 1 × 10−6 M, formononetin and biochanin A were capable of 
inducing about 35 and 25% relaxation, respectively. Since the cur-
rent study was the first to investigate interactions of isoflavones 
and ergot alkaloids, our rationale was to pick an intermediate 
concentration (1 × 10−6 M) to avoid extreme scenarios and one 
that was equimolar with the concentration of ergovaline. The 
concentration of ergovaline-containing tall fescue seed extract 
that was chosen (1 × 10−6 M) is based on the findings of Egert 
et  al. (15), where 1 ×  10−6  M of ergovaline-containing extract 
was observed to induce contractile response (about 40% of KCl 
maximum) of bovine mesenteric artery and vein.
Several studies have demonstrated that cattle grazing endo-
phyte-infected tall fescue had reduced contractile responses to 
5-hydroxytryptamine (5-HT) and as well as ergot alkaloids in the 
lateral saphenous vein (16, 17). Recently, a study using mesenteric 
artery and vein from steers that had been ruminally dosed with 
endophyte-infected tall fescue seed observed a decreased or com-
pletely absent constrictive response to ergot alkaloids (15). In the 
current study, an in vitro incubation of bovine mesenteric vascu-
lature in a medium containing EXT was used to achieve an ergot 
alkaloid pretreatment. The pretreatment of blood vessels with 
EXT (33) and isoflavones (F and B) were conducted at equimolar 
final concentrations of 1 × 10−6 M. It has been reported that F and 
B both induced vasorelaxation in phenylephrine-precontracted 
rat-isolated thoracic aorta at 1 × 10−6 M (29). This latter study 
identified both nitric oxide from endothelial nitric oxide synthase 
(NOS) and potassium efflux from endothelial cells as putative 
mechanisms of action. However, the 1 × 10−6 M ergovaline in the 
EXT may be considered a high dose compared to the physiologi-
cal levels encountered by cattle grazing endophyte-infected tall 
fescue (34). Nevertheless, the viability of mesenteric artery and 
vein was not compromised by concentration of ergot alkaloids 
used in the current study, as evidenced by the fact that both artery 
and vein were responsive to the final KCl addition.
Studies have reported that many isoflavones and their 
metabolites can reduce the vasoconstriction induced by KCl 
in several different vessel types using rat models (28, 35). The 
contractile response to KCl of endothelium-denuded rat aortic 
rings was inhibited by pretreatment with genistein or daidzein 
at both 3 × 10−5 and 1 × 10−4 M for 30 min (36). However, in 
the same study, pretreatment with genistein or daidzein at 
1 × 10−5 M did not relax the KCl-induced vasoconstriction. The 
similar dose-dependent inhibition of F (1 × 10−5, 3 × 10−5, and 
1 × 10−4 M) on the contractile response to KCl was observed in 
rat mesenteric arteries without endothelium (37), where F again 
failed to inhibit KCl-initiated contraction at 1 × 10−5 M. However, 
in endothelium-intact rat aortic rings, Zhao et al. (38) reported 
that pretreatment with 1 × 10−5, 3 × 10−5, and 5 × 10−5 M of F 
all significantly inhibited the contractile response to KCl in a 
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non-competitive manner. In the current study, the prior exposure 
to F (1 × 10−6 M), biochanin A (1 × 10−6 M), and their combina-
tion did not have an impact on maximum contractile response 
of mesenteric artery and vein to KCl in treatments either with or 
without EXT. Since previous studies have indicated that the inhi-
bition effects were dose-dependent (36, 37) and non-competitive 
(38), it is possible that the isoflavone concentration (1 × 10−6 M) 
in the current study was not high enough to elicit any inhibi-
tory effects on the KCl response. However, in the current study, 
maximum KCl responses were unaffected by F and B, which 
validate the usage of KCl as a reference compound to normalize 
the contractile responses.
There is limited information about isoflavones’ impact on 
blood vessel morphology in regards to vessel inside and outside 
diameters. In the current study, there was no significant evidence 
of an F or B effect on mesenteric artery inside or outside diameter 
regardless of EXT treatment. However, a tendency for a smaller 
inside diameter induced by F treatment was observed in mesen-
tery artery pretreated without EXT. One possible explanation for 
this could be the inhibitory effect of F on vascular smooth muscle 
cells. Previously, estrogens [tamoxifen (39), estradiol (40)] and 
isoflavones [F and B (41)] have been shown to inhibit mitogen-
induced proliferation, migration, and extracellular matrix 
synthesis of smooth muscle cells. On the other hand, the inside 
diameter of bovine lateral saphenous veins collected from steers 
grazing high-endophyte tall fescue pasture were smaller than 
those from steers grazing low-endophyte mixed-grass pasture 
(16). Likewise, Egert et al. (15) observed a smaller outside diameter 
of bovine mesenteric artery from endophyte-infected tall fescue 
seed-dosed steers than control steers. One possible explanation 
is the prolonged vasoconstriction induced by ergot alkaloids 
results in decreased inside or outside diameter. Additionally, the 
morphological changes of blood vessels, especially the expansion 
of the tunica media smooth muscle layer, could also lead to a 
smaller vessel insider diameter. It has been observed that calves 
given ethanolic extracts of tall fescue hay had symptoms of fescue 
foot and concomitant thickening of vessel walls and smaller vessel 
lumens in blood vessels of the coronary bands and tail tips (42). 
Similarly, Garner and Cornell (43) reported a thickening of the 
smooth muscle layer of peripheral blood vessels after consumption 
of endophyte-infected tall fescue. Although the exact mechanism 
associated with thickening of smooth muscle layer is unclear, 
evidence suggests hyperplasia over hypertrophy. Strickland et al. 
(44) reported that ergonovine, ergovaline, and α-ergocryptine 
stimulate the growth and mitosis of quiescent bovine vascular 
smooth muscle cells in vitro. Although, in the present study, there 
was no significant impact of F and B pretreatment on mesenteric 
artery inside or outside diameters, the tendency of larger inside 
diameter caused by F may indicate an alleviative effect on ergot 
alkaloids induced thickening of vessel walls and smaller lumens.
In the current study for pretreatments without EXT, ERT 
induced similar contractile response curves and −logEC50 values 
(Control, F, B, and F+B) in mesenteric arteries. The shape of 
contractile responses were similar with Egert et  al. (15), who 
reported ERT-induced contractile responses in mesenteric artery 
from steers, not exposed to ergot alkaloids, with a −logEC50 value 
of 6.03 ± 0.4 M. Whereas, the shape of mesenteric vein contractile 
response curves were in contrast to the observations of Egert et al. 
(15), which did not drop to negative values after reaching a maxi-
mum. Further, the maximum contractile response of mesenteric 
vein to ERT in the current study was also lower (10% vs. 45% of 
KCl maximum). The blood vessels used in the previous study (15) 
did not undergo an in vitro pre-myograph incubation and utilized 
blood vessels from steers compared to heifers in the current study.
Substantial evidence has shown that many ergot alkaloids are 
vasoconstrictive in multiple types of vessels in various animal 
models (7, 8). Among these vasoactive ergot alkaloids, ERT 
and ergovaline were indicated as more potent vasoconstrictors 
with lower EC50 values (relative to other alkaloids) in bovine 
saphenous vein (45), ruminal vasculature (13), and mesenteric 
vasculature (15). The current observation of the contractile 
response induced by ERT was consistent with the previous find-
ings in terms of vasoactivity for this alkaloid. Even though not 
completely defined yet, numerous studies have been conducted to 
investigate the mechanism of ergot alkaloid-caused vasoconstric-
tion. The structural similarities of the ergoline ring system and 
several biogenic amines [i.e., (nor)epinephrine, serotonin, and 
dopamine] allows ergot alkaloids to interact with corresponding 
biogenic amine receptors as ligands (30, 46). Substantial evidence 
has shown that ergot alkaloids interact with dopamine-2 recep-
tors (47, 48), α1-adrenergic receptors (49, 50), α2-adrenergic 
receptors (51), and 5-HT2A receptors (14, 16, 17). The binding 
with these G protein-coupled receptors activates the subunit of 
the heterotrimeric G protein and then triggers various secondary 
messaging systems and corresponding cytoplasmic signaling 
transductions. The vasoconstrictive response induced by ERT 
shown in the current study (Figure 2) could be explained by these 
agonistic mechanisms.
The pre-myograph incubation with EXT altered the contractile 
capacity of the mesenteric artery and vein. Using a bovine lateral 
saphenous vein model, Klotz et al. (16) found that 2,5-dimethoxy-
4-iodoamphetamine (DOI), a 5-HT2A receptor agonist, induced 
vessel contractile intensities were 35% lower in high endophyte-
infested tall fescue than in low-endophyte-infested tall fescue, 
whereas 5-carboxytryptamine (5-HT7 receptor agonist) produced 
greater (37%) contractile intensities in high endophyte-infected 
tall fescue. Taken together, this indicated that chronic exposure 
to ergot alkaloids through grazing endophyte-infested tall fes-
cue altered the vasoconstriction via serotonergic receptors. In 
a subsequent study, Klotz et  al. (17) reported a suppression of 
the contractile response to ergovaline and 5-HT in steers graz-
ing Kentucky-31 tall fescue infected with wild-type endophyte. 
Further, Egert et al. (15) demonstrated a similar reduced contrac-
tile response to ERT in mesenteric vasculature of steers treated 
with endophyte-infected tall fescue seed. Unsurprisingly, the 
antagonistic effects of ergot alkaloids to certain 5-HT receptors 
have been shown previously (49, 50, 52). Collectively, it is possible 
that the EXT pretreatment in the present experiment reduced the 
vasoconstriction to ERT via altering the biogenic amine receptor 
activities.
Many in vitro bioassays have demonstrated that, in various ves-
sel types and in numerous species, the binding of ergovaline and 
receptor was irreversible, or the dissociation from the receptor was 
very slow (14, 45, 50, 53). Likewise, an apparent bioaccumulation 
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was reported in bovine lateral saphenous veins after repetitive 
exposures of ergovaline in vitro (54). Additionally, studies have 
indicated that ergot alkaloid-induced constriction is prolonged 
and wash-resistant in human superficial temporal artery (55) 
and coronary artery (56). These findings may explain the high 
contractile response to the initial ERT addition (5 × 10−9 M) in 
mesenteric arteries that were pretreated with EXT (1 × 10−6 M 
ergovaline) in the current study. Furthermore, using an inositol 
phosphate accumulation assay, Unett et  al. (57) reported that 
as a 5-HT2B agonist, ERT maintained similar potencies after 
2 or 4-h extensive washout and this was due to internalization 
or sequestration of the active ERT-bound receptor. It has been 
demonstrated that ERT and ergovaline are equally potent vaso-
constrictors inducing similar contractile responses (45). Thus, 
these findings support the observations in the current study that 
the elevated contractile response to very low concentrations of 
ERT pretreated with EXT was numerically similar to 1 × 10−6 M 
ERT-induced contractile response of mesenteric artery without 
EXT incubation. This can be attributed to prior exposure to 
ergovaline (in EXT) leading up to the myograph portion of the 
experiment, and possible carry over of the vascular response to 
ergovaline to the dose response to ERT.
In the present study, prior exposure to F and B failed to con-
sistently alter the mesenteric vasculature contraction induced by 
ERT. As discussed earlier in this section, numerous studies have 
shown the vasodilative effect of isoflavones and their metabolites 
in different vessel types. Pretreatment with F (3  ×  10−5 and 
5 ×  10−5  M) antagonized contractile responses of rat thoracic 
aortas to norepinephrine in a non-competitive manner (38). Sun 
et al. (37) hypothesized that pre-incubation with F (3 × 10−5 and 
1 × 10−4 M) depressed the contraction of rat mesenteric artery 
to phenylephrine and 5-HT, and similarly, depression was not 
observed when F at 1 × 10−5 M. The 1 × 10−6 M F and B concentra-
tions in the present study were possibly not high enough to elicit 
sufficient vasorelaxation to offset the ERT-induced vasoconstric-
tion. Other evidence of the chronic antihypertensive effect of F 
has been reported based on male spontaneously hypertensive rats 
(SHR) (58). They found that the vasoconstriction of mesenteric 
artery segments induced by phenylephrine or 5-HT was reduced 
in F (50 mg/kg per day) orally administrated to SHR. The expres-
sion of α1-adrenoceptors and 5-HT2A/1B receptors in mesenteric 
artery of F treated SHR decreased (58).
Even though there might be some species differences between 
bovine and SHR, the 2-h pre-myograph incubation with F or B 
in the present study may not be long enough to permit expres-
sion or induction of NOS by the tissues that were used. However, 
sodium- and ATP-dependent K+ transport mechanisms, like 
those described by Wu et  al. (29), are very rapid. Further, F 
and B are metabolized to daidzein and genistein in the rumen 
(59). As many metabolic studies have found, daidzein is further 
metabolized by rumen and intestinal bacteria to equol, which has 
a higher estrogenic potency than its isoflavone precursor (22, 23, 
59). Equol undergoes renal clearance by clover-fed ruminants 
(60, 61), which indicates that equol, rather than formononetin, is 
present in the blood. It is possible that equol and other bacterial 
metabolites of isoflavones could have greater effects on bovine 
blood vessels. Thus, the different routes of administration of iso-
flavone treatments (in vivo vs. in vitro) may account some of the 
inconsistencies, and the idea that bacterial or animal metabolism 
might influence vasorelaxation is consistent with the aforemen-
tioned results by Sun et al. (58).
With EXT in the pretreatment media, F and B increased the 
contractile response of mesenteric artery at several ERT concen-
trations. This has provided the first evidence that the isoflavones, 
F and B, have potential to alleviate the vasoconstrictive effect of 
ergot alkaloids. However, based on the current knowledge from 
ergot alkaloids and isoflavones, there is little to mechanistically 
explain this phenomenon, so more investigations on their 
interactions are needed.
cOnclUsiOn
In conclusion, this study indicated that a pre-myograph incuba-
tion with F, B at 1 × 10−6 M and their combination did not affect 
the contractile response to ERT in mesenteric vasculature. The 
pre-myograph incubation of mesenteric vasculature with EXT 
(equivalent to 1 × 10−6 M ergovaline) reduced the vasoactivity of 
ERT, and there were some indications that F and B may alleviate 
this reduction. At higher concentrations, F and B may alleviate 
this reduction in vasoactivity caused by prior exposure to ergot 
alkaloids. Future studies with higher isoflavone dosages or longer 
exposure may be helpful to further investigate the ergot alkaloids 
and isoflavones interaction. Additionally, this study was confined 
to the mesenteric veins and arteries. It is plausible that effects 
could be elicited in other vessels with different expression levels of 
5-HT, NOS, or other factors. In vivo research, which takes isofla-
vone metabolism into account, is necessary to better understand 
the interaction from a practical perspective.
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